Zenas BioPharma, Inc.(ZBIO)Earnings, Financials & Key RatiosZenas BioPharma, Inc. (ZBIO) stock price & volume — 10-year historical chart
Zenas BioPharma, Inc. (ZBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Zenas BioPharma, Inc. (ZBIO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $1.46vs $1.37-6.6% | —vs $25M |
| Q2 2026 | Mar 16, 2026 | $1.10vs $1.00-9.8% | —vs $13M |
| Q4 2025 | Nov 12, 2025 | $1.22vs $0.87-40.2% | —vs $29M |
| Q3 2025 | Aug 12, 2025 | $1.25vs $1.02-22.5% | —vs $4M |
Recent stock market news and headlines for Zenas BioPharma, Inc. (ZBIO)
CEO Leon Moulder acquired 60,000 shares for a total value of approximately $1.01 million on May 18, 2026. This transaction represents 13.04% of his aggregate holdings prior to the transaction.
WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced that on June 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 100,000 shares of the Company's common stock (“Stock Options”) and an aggregate of 78,075 restricted stock units of the Company's common stock (“RSUs”) to newly hired employees of the Company as an inducement material to such employees' entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grant”).
Key metrics vs top competitors for Zenas BioPharma, Inc. (ZBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $24.67 | $1.1B | -2.92 | 100% | -3777.37% | -136.22% | — | |
| $6.82 | $193.85M | -2.84 | -51.43% | -173.47% | -36.55% | — | |
| $38.24 | $7.85B | -13.81 | — | — | -68.16% | — | |
| $6.06 | $1.49B | -23.31 | 22.09% | -13.58% | -38.11% | — | |
| $327.99 | $9.47B | -24.33 | -100% | — | -43.02% | — | |
| $116.46 | $9.51B | -31.56 | -16.72% | -612.17% | -25.02% | — |
Zenas BioPharma, Inc. (ZBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Zenas BioPharma, Inc. (ZBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 13, 2026·SEC
Mar 31, 2026·SEC
Mar 16, 2026·SEC
Get notified when ZBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Zenas BioPharma, Inc. (ZBIO) stock FAQ — growth, dividends, profitability & financials explained
Zenas BioPharma, Inc. (ZBIO) reported $10.0M in revenue for fiscal year 2025.
Zenas BioPharma, Inc. (ZBIO) grew revenue by 100.0% over the past year. This is strong growth.
Zenas BioPharma, Inc. (ZBIO) reported a net loss of $425.2M for fiscal year 2025.
Zenas BioPharma, Inc. (ZBIO) has a return on equity (ROE) of -136.2%. Negative ROE indicates the company is unprofitable.
Zenas BioPharma, Inc. (ZBIO) had negative free cash flow of $210.5M in fiscal year 2025, likely due to heavy capital investments.
